ClinicalTrials.gg
CompletedNCT02410213Updated Jul 25, 2022Results posted

A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

A Phase 2 interventional study of Ferric Carboxymaltose (FCM) in Iron Deficiency Anemia (IDA), sponsored by American Regent, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2022-07-25.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
41st of 57
35 · median 100
Started
2015
with 2 others
Phase 2
8 of 57
none open now
Registered
18th of 57
by date
Lead sponsor
11 of 57
American Regent, Inc.

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 41st largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 2, and was the 18th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

This is a Phase II, open-label, non-randomized, multi-center, single arm study to characterize the pharmacokinetic and pharmacodynamics (PK/PD) profile of Ferric Carboxymaltose dosing in pediatric subjects with IDA after receiving either a 7.5 mg/kg or 15 mg/kg dose of Ferric Carboxymaltose.

Read the detailed description

This is a Phase II, open-label, non-randomized, multi-center, single arm study to characterize the pharmacokinetic and pharmacodynamics (PK/PD) profile of Ferric Carboxymaltose dosing in pediatric subjects with IDA after receiving either a 7.5 mg/kg or 15 mg/kg dose of Ferric Carboxymaltose.

03

Conditions studied

  • Iron Deficiency Anemia (IDA)
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 1 to 17 years of age with assent to participation and his/her parent or guardian is willing and able to sign the approved by the Independent Review Board / Ethics Committee.
  • Screening TSAT \< 20%
  • Screening \< 11 g/dL
  • For subjects who are receiving an erythropoietin stimulating agent (ESA): stable ESA therapy (+/- 20% of current dose) for > 8 weeks prior to the qualifying screening visit and no ESA dosing or product changes anticipated for the length of the trial

Exclusion criteria

Exclusion Criteria:

  • Known reaction to any component of Ferric Carboxymaltose.
  • Subject previously randomized and treated in this study or any other clinical study of Ferric Carboxymaltose (FCM or VIT-45).
  • (BMI) ≤ 5th percentile for age (see APPENDIX 2)
  • Male or Female subject 1 year of age weighing \< 12kg.
  • History of acquired iron overload, hemochromatosis or other iron accumulation disorders.
  • Chronic kidney disease subjects on hemodialysis.
  • Screening Ferritin level > 300ng/mL
  • Subjects with significant severe diseases of the liver, hemopoietic system, cardiovascular system, psychiatric disorder or other conditions which on the opinion of the investigator may place a subject at added risk.
  • Any active infection.
  • Known positive antigen (HBsAg) or viral antibody (HCV) with evidence of active hepatitis.
  • Known positive -1/HIV-2 antibodies (anti-HIV).
  • Anemia due to reasons other than iron deficiency (i.e. hemoglobinopathy). Subjects treated with vitamin B12 or folic acid deficiency are permitted.
  • Intravenous iron and /or blood transfusion in the 4 weeks prior to screening.
  • therapy that may lead to anemia (i.e. cyclophosphamide, azathioprine, mycophenolate mofetil). Note therapy is permitted.
  • Administration and / or use of an product (drug or device) within 30 days of screening.
  • Alcohol or drug abuse within the past six months.
  • Female subjects who are pregnant or lactating, or sexually active female who are of not willing to use an acceptable form of precautions during the study.
  • Subject is unable to comply with study assessments.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller

    Drug: Ferric Carboxymaltose (FCM)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Serum Concentration (Cmax)

    Maximum observed serum concentration; obtained directly from the serum concentration-time profile.

    Time frame: prior to dosing and 1, 2, 6, 12, 48 and 72 hours post dosing

07

Results

Posted Nov 29, 2017

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Ferric Carboxymaltose (FCM) 7.5 mg/kgCohort 2: Ferric Carboxymaltose (FCM) 15 mg/kg
Started1619
Completed1619
Not completed00

Outcome measures

PrimaryMaximum Serum Concentration (Cmax)

Maximum observed serum concentration; obtained directly from the serum concentration-time profile.

Time frame:
prior to dosing and 1, 2, 6, 12, 48 and 72 hours post dosing
Reported as:
Mean · µg/mL
Maximum Serum Concentration (Cmax)
µg/mLCohort 1: Ferric Carboxymaltose (FCM) 7.5 mgCohort 2: Ferric Carboxymaltose (FCM) 15 mg/kg
Maximum Serum Concentration (Cmax)157 ± 33.8310 ± 13.9

Adverse events

Collected over Initial treatment with study drug through completion of day 35 (28 days post-dose for subjects who early terminated from the study).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Ferric Carboxymaltose (FCM) 7.5 mg/kg0/16 (0%)2/16 (12.5%)9/16 (56.3%)
Cohort 2: Ferric Carboxymaltose (FCM) 15 mg/kg0/19 (0%)0/19 (0%)12/19 (63.2%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Ferric Carboxymaltose (FCM) 7.5 mg/kgCohort 2: Ferric Carboxymaltose (FCM) 15 mg/kg
SinusitisInfections and infestations1/160/19
Upper Respiratory Tract InfectionInfections and infestations1/160/19
Most frequent other events
Showing 10 of 37
Most frequent other events
EventCohort 1: Ferric Carboxymaltose (FCM) 7.5 mg/kgCohort 2: Ferric Carboxymaltose (FCM) 15 mg/kg
RhinorhoeaRespiratory, thoracic and mediastinal disorders0/163/19
UrticariaSkin and subcutaneous tissue disorders0/163/19
PyrexiaGeneral disorders2/160/19
RashSkin and subcutaneous tissue disorders2/161/19
HyperthermiaGeneral disorders0/162/19
Upper respiratory tract infectionInfections and infestations1/162/19
ConstipationGastrointestinal disorders1/160/19
HaematocheziaGastrointestinal disorders1/160/19
Infusion site pruritusGeneral disorders1/160/19
ThirstGeneral disorders1/160/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)
Cohort 1 (FCM at 7.5 mg/kg to a maximum of 750mg)9.1 ± 6.13
Cohort 2 (FCM at 15 mg/kg to a maximum of 750mg)10.3 ± 5.77
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)
Cohort 1 (FCM at 7.5 mg/kg to a maximum of 750mg) — Female10
Cohort 1 (FCM at 7.5 mg/kg to a maximum of 750mg) — Male6
Cohort 2 (FCM at 15 mg/kg to a maximum of 750mg — Female9
Cohort 2 (FCM at 15 mg/kg to a maximum of 750mg — Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ferric Carboxymaltose (FCM)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White35
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)
Poland30
Russia5
08

Study locations

10 sites
  • Szpital Uniwersytecki Katedra i Klinika Pediatrii, Hematologii i Onkologii
    Bydgoszcz, 85-094, Poland
  • Zespół Opieki Zdrowotnej w Dębicy z siedzibą w Dębicy , Oddział Dziecięcy
    Dębica, 39-200, Poland
  • Uniwersytecki Szpital Dziecięcy w Krakowie, Oddział Pediatrii i Gastroenterologii (V)
    Kraków, 30-663, Poland
  • Klinika Hematologii, Onkologii i Transplantologii Dziecięcej Uniwersytecki Szpital Dziecięcy w Lublinie
    Lublin, 20-093, Poland
  • Oddział Ogólnopediatryczny; Uniwersytecki Szpital Dziecięcy w Lublinie
    Lublin, 20-093, Poland
  • Indywidualna Specjalistyczna Praktyka lekarska z siedzibą w Rzeszowie
    Rzeszów, 35-302, Poland
  • Klinika Pediatrii, Hematologii i Onkologii Dziecięcej
    Szczecin, 71-252, Poland
  • Klinika Gastroenterologii, Hepatologii, Zaburzeń Odżywiania i Pediatrii
    Warszawa, 04-730, Poland
  • State Budgetary Educational Institution of Higher Professional Education "Ryazan State Medical University named after academician I.P. Pavlov" of the Ministry of Health of the Russian Federation
    Ryazan', 390029, Russian Federation
  • State Educational Institution of Higher Professional Education Saint Petersburg State Pediatric Medical Acamy of Ministry of Health and Social Development of the Russian Federation
    Saint Petersburg, 194100, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Jan 2017, 23 months.

Results were first posted in Nov 2017, 10 months after primary completion.

Of 16 phase 2 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2015
First posted
Apr 7, 2015
StartActual
Feb 19, 2015
Primary completionActual
Jan 22, 2017
CompletionActual
Jun 1, 2017
Results first posted
Nov 29, 2017
Last update
Jul 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02410213
Responsible party
Sponsor
First posted
Apr 7, 2015
Start date
Feb 19, 2015
Primary completion
Jan 22, 2017
Completion
Jun 1, 2017
Results posted
Nov 29, 2017
Last update
Jul 25, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion